Global Cell Isolation/Cell Separation Market Industry Analysis and Forecast (2019-2026) – ScoopJunction

Global Cell Isolation/Cell Separation Market was valued US$ XX Bn in 2018 and is expected to reach US$ 17.92 Bn by 2026, at a CAGR of around XX % during a forecast period.

The report covers all the trends and technologies playing a major role in the growth of the Cell Isolation/Cell Separation market during the forecast period. It highlights the drivers, restraints, and opportunities expected to influence the market growth during 2019-2026.

Request For FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/market-report/global-cell-isolation-cell-separation-market/34136/#requestforsample

Some of the market drivers for the cell isolation/cell separation market are increasing incidences & prevalence of chronic diseases with the aging population, technological advancement in cell isolation, growing demand for bio-pharmaceuticals, personalized medicine, and increasing stem cell research. Cell isolation or separation is a tool used to sort cells into a specific population from a heterogeneous group of cells without contamination. The use of cell isolation techniques helps to open the door of cell-based therapies and thereby improve the quality of treatment and clinical outcome.

However, the ethical issues regarding the isolation of embryonic stem cells and the high cost of cell separation instruments are expected to restrict the growth of this market during the forecast period.

Based on cell type, the human cell segment is expected to register a major revenue share in the cell isolation/cell separation market globally. Owing to increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the high frequency and growing incidence of diseases such as cancer.

Based on the product, the consumables segment is expected to witness the fastest growth during the forecast period. Because of the increasing investments by companies to develop advanced products and the rising government initiatives for improving cell-based research are driving the growth of this segment.

North America region is expected to grow at a XX % rate of CAGR during the forecast period owing to increasing government support for cancer and stem cell research, the expanding biotechnology and biopharmaceutical industries and the increasing prevalence of chronic and infectious diseases in which cell isolation is required for diagnosis and treatment. Which results in, increase in demand for cell isolation products.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Cell Isolation/Cell Separation Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in Global Cell Isolation/Cell Separation Market.

Do Inquiry Before Purchasing Report Here: https://www.maximizemarketresearch.com/market-report/global-cell-isolation-cell-separation-market/34136/#inquiry

Scope of the Global Cell Isolation/Cell Separation Market

Global Cell Isolation/Cell Separation Market, By Product

Consumableso Reagents, Kits, Media, and Serao Beadso Disposables Instrumentso Centrifugeso Flow Cytometerso Magnetic-activated Cell Separator Systemso Filtration SystemsGlobal Cell Isolation/Cell Separation Market, By Cell Type

Human Cellso Differentiated Cellso Stem Cells Animal CellsGlobal Cell Isolation/Cell Separation Market, By Cell Source

Adipose Tissue Bone Marrow Cord Blood/Embryonic Stem CellsGlobal Cell Isolation/Cell Separation Market, By Technique

Centrifugation-based Cell Isolation Surface Marker-based Cell Isolation Filtration-based Cell IsolationGlobal Cell Isolation/Cell Separation Market, By Application

Biomolecule Isolation Cancer Research Stem Cell Research Tissue Regeneration & Regenerative Medicine In Vitro DiagnosticsGlobal Cell Isolation/Cell Separation Market, By End user

Research Laboratories and Institutes Hospitals and Diagnostic Laboratories Biotechnology and Biopharmaceutical Companies Other End UsersGlobal Cell Isolation/Cell Separation Market, By Region

North America Europe Asia Pacific Middle East & Africa South AmericaKay players operating in the Global Cell Isolation/Cell Separation Market

Thermo Fisher Scientific Beckman Coulter Becton, Dickinson and Company GE Healthcare Merck KgaA Miltenyi Biotech pluriSelect STEMCELL Technologies Inc. Terumo BCT Bio-Rad Laboratories Inc.

Browse Full Report with Facts and Figures of Cell Isolation/Cell Separation Market Report at: https://www.maximizemarketresearch.com/market-report/global-cell-isolation-cell-separation-market/34136/

MAJOR TOC OF THE REPORT

Chapter One: Cell Isolation/Cell Separation Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Isolation/Cell Separation Market Competition, by Players

Chapter Four: Global Cell Isolation/Cell Separation Market Size by Regions

Chapter Five: North America Cell Isolation/Cell Separation Revenue by Countries

Chapter Six: Europe Cell Isolation/Cell Separation Revenue by Countries

Chapter Seven: Asia-Pacific Cell Isolation/Cell Separation Revenue by Countries

Chapter Eight: South America Cell Isolation/Cell Separation Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Isolation/Cell Separation by Countries

Chapter Ten: Global Cell Isolation/Cell Separation Market Segment by Type

Chapter Eleven: Global Cell Isolation/Cell Separation Market Segment by Application

Chapter Twelve: Global Cell Isolation/Cell Separation Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +91 20 6630 3320/ +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read more here:
Global Cell Isolation/Cell Separation Market Industry Analysis and Forecast (2019-2026) - ScoopJunction

Can old drugs put a leash on wandering cancer cells? – Newsroom

health & science

Can an immune system distracted by post-surgery healing allow previously dormant cancer cells to wake up and cause havoc? Scientists say the science isnt settled but old drugs may help.

For years theres been a question surrounding breast cancer surgery. Twelve to 18 months after surgery theres a high recurrence rate of cancer.

It was a dilemma put to the test in mice, the results suggestingthe bodys healing response to surgery could be the reason.

The hypothesis is while the body is busy healing a wound, the immune system is less able to keep cancer cells - which had already spread to other areas of the body - dormant.

Surprisingly, the study found giving the mice over-the-counter anti-inflammatory medicine before and after surgery could reduce the risk.

The study received a fair bit of attention. There was worry from some quarters it may lead to people rejecting important surgery. It also highlighted something as cheap as aspirin could improve patients outcomes.

According to University of Otago research fellow Dr Nicholas Fleming, surgery is almost always the best option.

His view is the science on surgery and cancer-spread isnot settled, and while there may be a risk, not having surgery creates a worse situation.

If you cut a cancer out early, hopefully you get all of the cancer and thats the end of it.

The later the surgery, the greater the chance the cancer has spread.

He describes the question of what causes cancer to spread as a million-dollar question. Heputs it down to a collection of mutations.

For the most part, cancer cells do one thing:life revolves around dividing.

But in the tumour some rebels emerge. Not content to simply divide, they leave home and roam the body. Eventually, these find new spots to colonise. In their new home they begin to divide once more, creating new tumours.

Thats why the most important thing in cancer treatment is treating people before they get to that point because after that it becomes very, very hard to save their lives.

Fleming has been looking at whether existing drugs thatare out of patent(and dirt cheap as a result)couldhelp fight cancer spread.

The idea of repurposing drugs is an area gaining traction. It was sparked by data showing diabetics taking metformin for their diabetes had a lower rate of cancer than those not taking it.

Since then, hundreds of drugs - not initially designed with cancer in mind - have been associated with effects on cancer.

Association isnt rock solid proof. The gold standard of proof comes from expensive clinical trials.

For old drugs with expired patents, this is an issue. Theres no financial incentive for drug companies to fund clinical trials of drugs they wont profit from.

As a publicly-funded researcher, Fleming is in a position to look at some of the off-patent drugs pharmaceutical companies arent interested in.

Rapamycin, used since the 1970s to stop transplants from being rejected, is one drug hes looked at. He describes it as anti-inflammatory and anti-migratory.

That drug can stop cells crawling. If you have cells that are migrating, you can stop them with that.

Fleming, who is also looking at pairing old drugs with the new immunotherapy drugs, is not the only scientist in New Zealand looking at repurposed drugs.

Gillies McIndoe Research Institute executive director Dr Swee Tans clinical trial is treating brain cancer with drugs thatcost $5 once every three months.

Its the worst brain cancer, its the most aggressive brain cancer. The median survival is that half the patients will die within 15 months after diagnosis. About half of them will recur within six months of treatment and once they have recurred, about half will die in six months.

He said 11 people currently in the trial wereliving longer than expected. The treatment uses blood pressure pills.

We say cancer is caused by stem cells that have misbehaved and caused cancer.

Tan uses the analogy of a beehive. A queen bee stem cell makes worker bees thatcreate the tumour, it also makes another queen bee thattravels elsewhere in the body and starts another hive.

He found the renin-angiotensin system, which regulates blood pressure and electrolyte balance, also controls the queen bee.

The implication is you might be able to design treatment to control cancer by controlling the cancer stem cells by using medications which control the renin-angiotensin system.

Delaying clinical proof is funding.

New Zealand spends $1 billion a year to treat cancer. That cost is escalating because of very expensive cancer drugs. If the government put aside 1 percent of that - $10 million a year to fund research like this - it will take this whole debate forward. It would allow the work to be done to prove it one way or the other.

Dr David Jennings, a Bay of Islands GP, thinks theres a case for not waiting for clinical trials.

As a GP hes seen the fireworks of cancer spread in patients. He also lost a close friend, and the process of trying to help turned him into an advocate for repurposed drugs.

His friends cancer had spread by the time it was diagnosed, but Jennings believes the repurposed drugs in conjunction with traditional cancer treatments extended his time, and improved its quality.

Lets say were losing 1000 patients a year, in 10 yearsthats 10,000 people. Thats a hell of a lot of people waiting for these studies to be done.

While clinical trials struggle to get funding, he thinks patients can take a lead, do research and talk to their GP. With repurposed drugs having been around for decades, side effects are well-known.

Were in a good position in New Zealand in terms of being able to repurpose drugs, but it will have to be a patient and doctor decision.

Read more:

Off-label and untapped - are old drugs new cancer treatments?

See more here:
Can old drugs put a leash on wandering cancer cells? - Newsroom

Sask. woman reflects on cancer journey before leading inaugural Multiple Myeloma March – News Talk 980 CJME

Southey's Mona Neher is leading the inaugural Multiple Myeloma March in Regina on Sept. 22, 2019. (Mona Neher/Submitted)

For the past decade, Mona Neher has wanted to hold a Multiple Myeloma March in Regina but she knew she couldnt do it alone.

This weekend, with help from others who have the same cancer, the Southey woman is making her dream a reality.

Neher was first diagnosed with myeloma (a form of blood cancer that targets plasma cells) in 2006 two years after fracturing her tailbone and ribs in a horseback-riding accident.

I had rib pain and fatigue, and I was wondering why this was going on, so I went to my doctor. Eventually, he sent me for X-rays and the X-rays came back with multiple myeloma, she remembered in an interview earlier this week.

At 39 years old with a young family at home, Neher said the diagnosis left her in a state of shock.

In the months that followed, she drove to Saskatoon for a stem cell transplant. With the help of the surgery and a phase two clinical medication trial, Neher launched into remission and back into the workforce as a registered nurse for 10 years.

In 2015, that familiar fatigue and pain picked up again, signalling that the cancer had returned. A year later, Neher underwent a second stem cell transplant that helped transition her back into remission, where she remains today.

While shes no longer working as a nurse, Neher now has a full-time job as an advocate, helping raise awareness about myeloma and holding support group meetings for those with the disease.

It might be a different type of myeloma (for each support group member) but we do understand what each other is going through and it just gives you strength to carry on, she explained.

With help from some of those support group members, Neher is leading the inaugural Multiple Myeloma March in Regina on Sunday. It starts at 10 a.m. at the RCMP Heritage Centre.

Neher said the event is a longtime coming; she has wanted to hold a march since it first originated 11 years ago.

Ive very happy about it and emotional about it, too, that it has finally come to this point. Im excited, she said.

Neher said there are two main goals of the five-kilometre walk: To raise $10,000 for research toward finding a cure to myeloma, and to help connect those newly diagnosed with the cancer.

I want (others with myeloma) to be positive and I know thats not necessarily what somebody wants to hear sometimes but there is hope, she encouraged. I know Im grateful for where Im at today, but it has been a journey.

Go here to see the original:
Sask. woman reflects on cancer journey before leading inaugural Multiple Myeloma March - News Talk 980 CJME

Circulating Tumor Cells and Cancer Stem Cells Market Estimated to Expand at a Robust CAGR over 2025 – Commerce Gazette

The tumor cells which have shed into lymphatic system and circulated over the body through blood circulation are called as circulating tumor cells. Circulating tumor cells may comprise seeds for metastasis. Stem cells are the type of cells that can differentiate into specialized cells and have the capacity of self-renewal. Cancer stem cells are the cancer cells that possess the characteristics of normal stem cells. Cancer stem cells are said to be responsible for relapse of cancers in patients. There is a growing interest in these two cell types due to their fundamental biological and clinical implications. Circulating tumor cells and cancer stem cells are an important element in order to understand cancer related mechanism and to find a cure from all type of cancers. These cells can be used for detecting of metastasis and the patients who are at a higher risk of cancer relapse.

The global circulating tumor cells and cancer stem cells market is anticipated to grow at a rapid rate owing to development in biotechnology and biomedical engineering. According to WHO, Cancer is the leading cause of mortality and morbidity globally impacting about 14 million people annually, leading to rapid increase in research activities worldwide. Circulating tumor cells and cancer stem cells are under research for various types of cancer such as breast cancer, lung cancer, colorectal cancer, skin cancer. Government and various government bodies are taking interest and initiative to boost funds and activities which is one of the major factor driving the growth of the global circulating tumor cells and cancer stem cells market. Increase in demand of oncology screening, diagnosis and treatment monitoring the patients disease progression is one of the factor likely to propel the growth of the market through 2024. Furthermore, application of the circulating tumor cell for the drug discovery, use of cells in development of tumor specific biomarkers for targeted therapies are driving the growth of the global market. However, the ethical issues involved in research and regulation to perform human trials are some of the major factor that are retraining the growth of the global market.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/13306?source=atm

Based on technology type, the global circulating tumor cells and cancer stem cells market is divided into following Cell enrichment Detection CTC Analysis

Based on Application types, the global circulating tumor cells and cancer stem cells market is divided into following Biomarkers Tumorigenesis Stem cell research Others

The global circulating tumor cells and cancer stem cells market is segmented on the basis of technology type, application type and geographical region. On the basis of technology type the global market is divided into cell enrichment, Detection and CTC Analysis. Enrichment is further divided into positive selection, negative selection, Microchips and others. Detection is further divided into Immunocytochemicals technology, Molecular based technology, EPISPOT functional invitro assay. Cell Enrichment accounted for the largest market share globally owing to higher usage in oncology research and highly accurate technology. Microchip technology is expected to register high growth in the global market due to introduction of cluster chip technology which enables to capture the clusters of circulating tumor cells. On the basis of application type, the global market is divided into Biomarkers, tumorigenesis, stem cell research and others.

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/13306?source=atm

Geographically the global circulating tumor cells and cancer stem cells market is divided into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is the dominating region in the global market attributing to the factors like developed economy, developed healthcare domain, strong funding for oncology research, rise in prevalence rate of cancer, favorable initiatives by government bodies. Asia Pacific region is expected to register high growth during the forecast period as a result of awareness, development of research and healthcare domains and prevalence of cancer.

Some of the major player operating in the global circulating tumor cells and cancer stem cells market are QIAGEN Hannover, AVIVA Biosciences, Epic Sciences, ApoCell, Cynvenio Biosystems, Fluxion Biosciences, Rarecells, Janssen Diagnostics, LLC, CellTraffix Inc., Silicon Biosystems, Advanced Cell Diagnostics, Inc. among others worldwide. To maintain a significant position in the global market key players are involved in collaboration with the cancer research universities and hospitals, for example in November 2015 Epic Sciences announced collaboration Abramson cancer Centre of University Pennsylvania. This collaboration is expected to explore the field of biomarkers which are identified by circulating tumor cells. The key participants are expanding the market by developing the facilities in different regions. For example, in September 2014 advanced cell diagnostic Inc. established a subsidiary in Europe to serve the European market.

The report covers exhaustive analysis on: Circulating Tumor Cells and Cancer Stem Cells Market Segments Circulating Tumor Cells and Cancer Stem Cells Market Dynamics Historical Actual Market Size, 2013 2015 Circulating Tumor Cells and Cancer Stem Cells Market Size & Forecast 2016 to 2024 Circulating Tumor Cells and Cancer Stem Cells Market Current Trends/Issues/Challenges Competition & Companies involved Circulating Tumor Cells and Cancer Stem Cells Market Drivers and Restraints

Regional analysis includes North America Latin America Europe Asia Pacific Middle East & Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Request to view TOC at https://www.persistencemarketresearch.com/toc/13306?source=atm

Read the original here:
Circulating Tumor Cells and Cancer Stem Cells Market Estimated to Expand at a Robust CAGR over 2025 - Commerce Gazette

Global Induced Pluripotent Stem Cells (iPSCs) Market Size, Status and Forecast 2019-2025 – Rapid News Network

In this report, the Global Induced Pluripotent Stem Cells (iPSCs) market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Global Induced Pluripotent Stem Cells (iPSCs) market has been broken down by major regions, with complete market estimates on the basis of products/applications on a regional basis.

Browse full research report at https://www.crystalmarketreport.com/global-induced-pluripotent-stem-cells-ipscs-market-size-status-and-forecast-2019-2025

QY research recently published a report, titled Global Induced Pluripotent Stem Cells (iPSCs) Market Insights, Forecast to 2025. The research includes collation of data that is gathered using primary and secondary research methodologies. The research is conducted by professionals who have remarkable expertise in the field. The report elaborates on all the aspect of the market for a comprehensive understanding of the market dynamics. The market is divided into various segments and all the segments follow a similar format for a detailed explanation of the market.

In report covers both sales and revenue and studies the segments pertaining to application, products, services, and regions. To assess the markets future the research report also discusses the competitive landscape present in the global Induced Pluripotent Stem Cells (iPSCs) market.

In 2018 the global Induced Pluripotent Stem Cells (iPSCs) market size was 72 million US$ and will reach 160.9 million US$ by 2025, with a CAGR of 12.2% during the forecast period.

Global Induced Pluripotent Stem Cells (iPSCs) Market: Scope of the Market

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells.

The report first uses historic data from different companies. The data collected is used to analyses the growth of industries in the past years. It includes data from the year 2014 to the year 2019. The forecast data provides the reader with an understating of the future of the market. The same data is used to predict the expectation of the companies and how they are expected to evolve in the coming years. The research provides historical as well as estimated data from the year 2019 to 2025. The details in the report give a brief overview of the market by examining its historical data, the current data, and forecast data to understand the growth of the market.

Global Induced Pluripotent Stem Cells (iPSCs) Market: Segment Analysis

The report also outlines the sales and revenue generated by the global Induced Pluripotent Stem Cells (iPSCs) market. It is broken down in many segments, such as regional, country level, by type, application, and others. This enables a granular view of the market, focusing on the government policies that could change the dynamics. It also assesses the research and development plans of the companies for better product innovation.

The report is based on research done specifically on consumer goods. The goods have bifurcated depending on their use and type. The type segment contains all the necessary information about the different forms and their scope in the global Induced Pluripotent Stem Cells (iPSCs) market. The application segment defines the uses of the product. It points out the various changes that these products have been through over the years and the innovation that players are bringing in. The focus of the report on the consumer goods aspect helps in explaining changing consumer behavior that will impact the global Induced Pluripotent Stem Cells (iPSCs) market.

Fujifilm Holding Corporation (CDI) was the global largest Players in Induced Pluripotent Stem Cells (iPSCs) industry,with the market share of 39% in 2018,followed by Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL.

Global Induced Pluripotent Stem Cells (iPSCs) Market: Regional Segment Analysis

Based on region, the global Induced Pluripotent Stem Cells (iPSCs) market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Central & South America. Asia Pacific has a large population, which makes its market potential a significant one. It is the fastest-growing and most lucrative region in the global economy. This chapter specifically explains the impact of population on the global Induced Pluripotent Stem Cells (iPSCs) market. Research views it through a regional lens, giving the readers a microscopic understanding of the changes to prepare for.

The report covers different aspects of the market from a consumer goods point of view. It aims to be a guiding hand to interested readers for making profitable business decisions.

The following players are covered in this report:

Fujifilm Holding Corporation (CDI)

Ncardia

Sumitomo Dainippon Pharma

Astellas Pharma Inc

Fate Therapeutics, Inc

Pluricell Biotech

Cell Inspire Biotechnology

ReproCELL

Induced Pluripotent Stem Cells (iPSCs) Breakdown Data by Type

Human iPSCs

Mouse iPSCs

Human iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs.

Induced Pluripotent Stem Cells (iPSCs) Breakdown Data by Application

Academic Research

Drug Development and Discovery

Toxicity Screening

Regenerative Medicine

Academic Research is the largest segment of Induced Pluripotent Stem Cells (iPSCs) application,with a share of 32% in 2018.

Browse full research report at https://www.crystalmarketreport.com/global-induced-pluripotent-stem-cells-ipscs-market-size-status-and-forecast-2019-2025

Reasons to Buy This Research Report

About Crystal Market Reports

Crystal Market Reports is a distributor of market research spanning 160 industries. Our extensive database consists of over 400,000 quality publications sourced from 400 plus publishers, this puts our research specialists in the unique position of been able to offer truly unbiased advice on what research provides the most valuable insights.

Contact Info.:-

Address: 90 State StreetSuite 700 AlbanyNew York 12207Email: [emailprotected]Web: https://www.crystalmarketreport.com

More here:
Global Induced Pluripotent Stem Cells (iPSCs) Market Size, Status and Forecast 2019-2025 - Rapid News Network

Global Stem Cell Therapy Market Analysis and Forecast, 2019-2029: Focus on Treatment Type, Cell Source, Indication,11 Countries’ Data, and Competitive…

DUBLIN, Sept. 20, 2019 /PRNewswire/ -- The "Global Stem Cell Therapy Market: Focus on Treatment Type, Cell Source, Indication,11 Countries' Data, and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Key Questions Answered in this Report:

The Global Stem Cell Therapy Industry Analysis projects the market to grow at a significant CAGR of 27.99% during the forecast period, 2019-2029.

The global stem cell therapy market growth has been primarily attributed to the major drivers in this market such as the increasing prevalence of chronic diseases, rising number of clinical trials for cell-based therapy, steady investment, and consolidation in the regenerative medicine market, and favorable regulatory environment.

The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include product approvals, declining product price, and increasing adoption rate.

However, there are significant challenges which are restraining the market growth. High treatment cost, the exorbitant cost required for set up, and ethical considerations related to the use of embryonic stem cells are the challenges faced by the market.

Key Topics Covered:

Executive Summary

1 Product Definition

2 Scope of the Work2.1 Overview: Report Scope2.2 Segmentation of the Global Stem Cell Therapy Market2.3 Assumptions and Limitations2.4 Key Questions Answered in the Report2.5 Base Year and Forecast Period

3 Research Methodology3.1 Overview: Report Methodology

4 Global Stem Cell Therapy Market4.1 Market Overview4.2 Introduction of Stem Cell Therapy4.3 Application of Stem Cells in Different Therapeutic Areas4.4 Market Dynamics4.5 Global Market Scenario4.6 Assumptions and Limitations

5 Competitive Landscape5.1 Overview5.2 Key Developments and Strategies5.2.1 Collaborations, and Partnerships5.2.2 Approvals and Clinical Studies5.2.3 Funding5.2.4 Business Expansions5.2.5 Product Launches and Developments5.2.6 Mergers and Acquisitions5.2.7 Others5.3 Market Share Analysis

6 Industry Insights6.1 Regulatory Scenario6.2 Regulatory Designations6.3 Expedited Designation Vs. Traditional Approval Timelines:6.4 Regulatory Challenges:

7 Global Stem Cell Therapy Market (by Treatment Type)7.1 Overview7.2 Key Trends of the Global Stem Cell Therapy Market (by Treatment Type)7.3 Autologous Treatment7.4 Allogenic Treatment

8 Global Stem Cell Therapy Market (by Cell Source)8.1 Overview8.2 Key Trends of the Global Stem Cell Therapy Market (by Cell Source)8.3 Bone Marrow and Peripheral Blood8.4 Adipose Tissue8.5 Placenta and Umbilical Cord8.6 Embryo8.7 Others

9 Global Stem Cell Therapy Market (by Indication)9.1 Overview9.2 Key Trends of the Global Stem Cell Therapy Market (by Indication)9.3 Orthopaedic and Dental9.4 Wounds and Injuries9.5 Cardiology and Neurology9.6 Immunology and Inflammatory9.7 Oncology and Metabolism9.8 Others

10 Global Stem Cell Therapy Market (by Region)10.1 Overview10.2 North America10.2.1 Overview10.2.2 U.S.10.2.3 Canada10.3 Europe10.3.1 Overview10.3.2 Germany10.3.3 U.K.10.3.4 France10.3.5 Italy10.3.6 Rest-of-Europe10.4 Asia-Pacific10.4.1 Overview10.4.2 Japan10.4.3 Australia10.4.4 China10.4.5 South Korea10.4.6 India10.4.7 Rest-of-Asia-Pacific10.5 Rest-of-the-World10.5.1 Overview10.5.2 Middle East and Africa10.5.3 Latin America

11 Company Profiles

Story continues

For more information about this report visit https://www.researchandmarkets.com/r/nyrlw5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-stem-cell-therapy-market-analysis-and-forecast-2019-2029-focus-on-treatment-type-cell-source-indication11-countries-data-and-competitive-landscape-300922435.html

Here is the original post:
Global Stem Cell Therapy Market Analysis and Forecast, 2019-2029: Focus on Treatment Type, Cell Source, Indication,11 Countries' Data, and Competitive...

4 Stocks to Focus on Global Biotechnology Reagents Market – Yahoo Finance

Advancement in the field of biotechnology along with growing need of reagents in drug testing and stem cell research is pushing demand for biotechnology reagents worldwide. Therefore it would be prudent to take a look at a couple of stocks operating in the segment that are poised to gain from the trend.

Promising Growth for Biotechnology Reagents

The global biotechnology reagents market is poised for impressive growth, according to a reportby research firm Research and Markets. Increasing research on stem cells is a major factor pushing this industry. Per the research firm, the industry is set to witness a compound annual growth rate of about 9% during the forecast period 2019-2023.

Trends Driving Demand for Reagents

The biotechnology sector has been doing remarkably well this year, despite the lackluster performance by the broader healthcare sector. In fact, the SPDR S&P Biotech ETF (XBI) has outperformed the broader Health Care Select Sector SPDR Fund (XLV) on a year-to-date basis. The former has increased 15.2% while the latter has only moved 6.2% higher.

The increasing use of biotechnology reagents is a prominent reason behind the significant growth of the biotechnology sector. Reagents are a crucial element in the area of drug discovery and these have high demand in research, therapeutics and commercial applications.

This is why biotechnology reagents have attracted heavy investments in research and development lately and will continue to do so. In fact, reagents have a rather broad spectrum of application in stem cell research. These are used as biomarkers to visualize cell and tissue lines.

Stem cell research is growing by leaps and bounds, thanks to its many benefits that include treatment of an array of diseases. Therefore with the rise in stem cell research, demand for reagents is poised to rise as well.

Our Choices

We have therefore chosen four stocks that are revolutionizing the global biotechnology reagents market which investors could consider in their portfolio. All of these stocks carry a Zacks Rank #2 (Buy) or 3 (Hold).

Agilent Technologies, Inc. A is an analytical laboratory instrument manufacturing company. The companys Dako brand offers high-quality reagents, diagnostic antibodies, instruments and software solutions that assist in the treatment of cancer patients.

Agilent Technologies carries a Zacks Rank #2. The companys stock price has outperformed the Zacks Electronics - Testing Equipmentmarket on an annualized basis (+10.4% vs +0.6%). The Zacks Consensus Estimate for its current-year earnings has risen 1% over the past 60 days. You can seethe complete list of todays Zacks #1 Rank stocks here.

Story continues

Danaher Corporation DHR is a conglomerate and manufacturer of medical products. The companys life sciences wing offers sophisticated equipment for biological research.

Danaher carries a Zacks Rank #2. The companys stock price has already outperformed the Zacks Diversified Operationsmarket on a year-to-date basis (+34.9% vs -5.2%). The Zacks Consensus Estimate for its current-year earnings has risen 0.2% over the past 60 days.

Thermo Fisher Scientific Inc.TMO is a manufacturer of analytical instruments, equipment and reagents.

Thermo Fisher Scientific carries a Zacks Rank #3. The companys stock price has outperformed the Zacks Medical - Instrumentsmarket on a year-to-date basis (+21.3% vs -5.7%). The Zacks Consensus Estimate for its current-year earnings has risen 0.4% over the past 60 days.

General Electric Companys GE life sciences wing operates in the cell and gene therapy industry. The company offers end-to-end solutions that include software and equipment that drive uniformity to dependable reagents.

General Electric carries a Zacks Rank #3. The stock price has outperformed the Zacks Diversified Operationsmarket on a year-to-date basis (+24.5% vs +20.3%). The Zacks Consensus Estimate for its current-year earnings has risen 1.6% over the past 60 days.

Just Released: Zacks 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportDanaher Corporation (DHR) : Free Stock Analysis ReportGeneral Electric Company (GE) : Free Stock Analysis ReportThermo Fisher Scientific Inc. (TMO) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

See original here:
4 Stocks to Focus on Global Biotechnology Reagents Market - Yahoo Finance

Editing Muscle Stem Cells with CRISPR Treats Mouse Model of Muscular Dystrophy – DocWire News

A research team from the University of Missouri School of Medicine has recently used CRISPR to edit a genetic mutation that contributes to Duchenne muscular dystrophy (DMD). This rare and debilitating genetic disorder is characterized by loss of muscle mass and physical impairment. By using this powerful gene-editing technology, these MU School of Medicine researchers have successfully treated mouse models of the disease. This work was published this summer in the journal Molecular Therapy.

Those with DMD possess a specific mutation that hinders the production of the dystrophin protein, which contributes to the structural integrity of muscle tissue. In the absence of this protein, the muscle cells weaken and eventually die. Pediatric patients with the condition often lose their ability to walk and can even lose the function of muscles that are essential for respiration and heart contractions.

Research has shown that CRISPR can be used to edit out the mutation that causes the early death of muscle cells in an animal model, explained senior author Dongsheng Duan, PhD, Margaret Proctor Mulligan Professor in Medical Research in the Department of Molecular Microbiology and Immunology at the MU School of Medicine. However, there is a major concern of relapse because these gene-edited muscle cells wear out over time. If we can correct the mutation in muscle stem cells, then cells regenerated from the edited stem cells will no longer carry the mutation. A one-time treatment of the muscle stem cells with CRISPR could result in continuous dystrophin expression in regenerated muscle cells.

Working alongside other researchers from MU, the National Center for Advancing Translational Sciences, Johns Hopkins School of Medicine and Duke University, Duan aimed to genetically modify muscle stem cells in mice. These scientists first edited the gene using an adeno-associated virus known as AAV9. Being this specific viral strain was recently approved by the FDA in treating spinal muscular atrophy, the researchers saw it as a viable candidate in treating DMD.

We transplanted AAV9 treated muscle into an immune-deficient mouse, said lead author Michael Nance, an MD-PhD program student in Duans lab. The transplanted muscle died first then regenerated from its stem cells. If the stem cells were successfully edited, the regenerated muscle cells should also carry the edited gene.

Upon analyzing the regenerated muscle tissue, the researchers found that its cells contained the edited gene, supporting their reasoning. The team then tested whether the muscle stem cells in mice with DMD could be genetically edited using CRISPR. These findings also supported their hypothesis, with the stem cells in the diseased tissue sustaining these edits and the regenerated cells successfully producing dystrophin.

This finding suggests that CRISPR gene editing may provide a method for lifelong correction of the genetic mutation in DMD and potentially other muscle diseases, explained Duan. Our research shows that CRISPR can be used to effectively edit the stem cells responsible for muscle regeneration. The ability to treat the stem cells that are responsible for maintaining muscle growth may pave the way for a one-time treatment that can provide a source of gene-edited cells throughout a patients life.

Duan and colleagues hope that future research will help this stem cell CRISPR therapy become a revolutionary treatment for children with DMD.

Link:
Editing Muscle Stem Cells with CRISPR Treats Mouse Model of Muscular Dystrophy - DocWire News

Mutant Tau Stiffens Axon Cytoskeleton Near Soma – Alzforum

20 Sep 2019

Changes to the microtubule-binding protein tau cause it to fall off these struts and aggregate, forming neurofibrillary tangles. But is that the reason for tau toxicity? A study in the September 18 Neuron suggests that V337M tau, a variant associated with frontotemporal dementia, causes morphological changes at the base of the axon. Scientists led by Li Gan, then at the Gladstone Institute of Neurological Disease, San Francisco, found that neurons derived from patients with the mutation are hyperexcitable. They had unusually short, unresponsive axon initial segments (AIS), which usually initiate action potentials and steer neuronal plasticity. Gans results suggest that this FTD mutation robs neurons of a mechanism for maintaining electrical homeostasis.

The initiation of axon potential firing has received little attention in neurodegeneration research, said Jrgen Gtz, What I really like about this paper is the use of complementary techniques to mechanistically dissect the effect of FTD mutant tau on neuronal function.

Because many FTD-causing tau mutations occur in the microtubule-binding domain, scientists believed they lead to disease by weakening microtubules (Rossi and Tagliavini, 2015; Hong et al., 1998). However, studies have mostly found that removing tau leaves microtubules intact (Roberson et al., 2007). On the other hand, FTD patients have hyperexcitable neurons, seizures, and highly synchronized neuronal networks (Beagle et al., 2017). Could the mutant protein alter neuronal excitability in some way?

Plasticity Deficit. In iPSC-derived wild-type neurons (left) the axon initial segment (green) is long initially (top)and shrinks after chronic depolarization with KCl (bottom). In neurons with V337M tau (right), the AIS starts out and remains short. [Courtesy of Sohn et al., 2019.]

To find out, first author Peter Dongmin Sohn and colleagues focused on the AIS. The closest part of the axon to the soma, the AIS contains a high concentration of voltage-gated ion channels and triggers action potentials. It regulates neuronal excitability by lengthening or shrinking in response to less or more activity, respectively. This remodeling relies on a reorganization of the cytoskeleton, in particular ankyrin G. Staining for AnkG revealed that the AIS shrank, making it less excitable, when Sohn and colleagues depolarized wild-type neurons for two days (see image at left). In contrast, in iPSC-derived neurons from a patient with the V337M tau mutation, the AIS was about 20 percent shorter to begin with, and chronic depolarization did not change its length. This suggested the region was less plastic. If the researchers used CRISPR-Cas9 to correct the mutation, then the initial length of the AIS and its plasticity matched that of wild-type cells.

The researchers next compared electrophysiological properties of mutant and control neurons. In culture, neurons carrying mutant tau more often fired in synch, having longer network bursts containing more spikes, than did wild-type neurons. This suggested the mutated tau caused a type of hyper-synchrony. After a two-day depolarization, these neurons fired six times faster, while the rate stayed steady in isogenic controls.

To find out how the mutant tau might be interfering with homeostatic control of neuronal excitability, the authors examined tau binding partners in the AIS. Tau interacts with end-binding protein 3 (EB3), another component of the AIS cytoskeleton (Sayas et al., 2015). EB3 stabilizes the AIS by linking microtubules to AnkG.

Getting a Grip. At left, wild-type tau (blue) binds EB3 (green), which anchors AnkG (yellow) to microtubules (white). To the right, mutant tau (red) binds more tightly to EB3 and clamps it in place, making the AIS rigid and unchanging. [Courtesy of Sohn et al., 2019.]

Sohn and colleagues determined that tau binds EB3 directly, and that V337M tau does so more tightly. In tau V337M neurons, EB3 levels in the AIS were 40 percent higher than in wild-type. Whats more, rather than distributing throughout the AIS cytosol, EB3 gathered just under the plasma membrane, corralling AnkG. In all, the data suggested that through its grip on EB3, tau concentrated the protein in the AIS and immobilized AnkG such that it couldnt respond to electrical activity.

Would removing EB3 rescue plasticity in V337M neurons? Suppressing translation with siRNA, Sohn reduced levels by 80 percent, which restored both the length and plasticity of the AIS. Reducing mutant tau in these neurons by 40 percent had similar effectsEB3 levels shrank in the AIS, and plasticity was restored.

Our study provides a completely different explanation for why tau is toxicnot because it forms aggregates, but because it binds to cytoskeletal proteins important for plasticity and makes rigid structures, Gan, who has since moved to Weill Cornell Medicine, New York, told Alzforum. This is an unexpected aspect of tau pathology. Gan plans to test whether this is true in other FTD mutations, and wonders about tau-induced hyperexcitability in Alzheimers disease, in which tau is not mutated.

This study provides an important demonstration of the utility of human iPSC models to reveal changes in neuroplasticity that may lead to disruption of brain circuitry over the course of disease, wrote Stephen Haggarty, Massachusetts General Hospital, Boston, to Alzforum. [It] provides further validation of therapeutic strategies seeking to reduce expression of pathological forms of tau.

Not all tau mutations work in this manner. In the September 19 Stem Cell Reports, researchers led by Hideyuki Okano of Keio University, Tokyo, report a different effect of the R406W. This mutation lies outside the microtubule-binding domain, but has nevertheless been reported to impede tau binding to those intracellular rails. Also using patient-derived neurons, first author Mari Nakamura and colleagues found that R406W tau mislocalizes to dendrites, as was seen before in cell and animal overexpression models (Thies and Mandelkow, 2007; Jan 2011 news). There it disrupts mitochondrial transport and causes axonal degeneration.

In neither study do the cell models rely on overexpression of the mutant tau protein, thereby overcoming issues often inherent to artificially engineered systems, Haggarty wrote.Gwyneth Dickey Zakaib

See the original post:
Mutant Tau Stiffens Axon Cytoskeleton Near Soma - Alzforum

Testing chemicals for birth defects using stem cells, not mice – UC Riverside

Researchers at the University of California, Riverside, are part of an ambitious plan at the U.S. Environmental Protection Agency, or EPA, to eliminate animal testing by 2035. Their contribution: developing a way to test whether chemicals cause musculoskeletal birth defects using lab-grown human tissue, not live animals.

Nicole zur Nieden, an associate professor of molecular, cell, and systems biology, and David Volz, an associate professor of environmental toxicology, are both experts on alternatives to regulatory toxicity testing and chemicals policy and regulation. They received $849,811 to grow human stem cells into bone-like tissue to test industrial and environmental chemicals that might interfere with fetal growth.

Birth defects that affect musculoskeletal tissues can be caused by chemical ingredients in pesticides, fungicides, paints, and food additives. Harmful chemicals must be identified through testing in order to be regulated. Currently, this testing is done on live animals, usually rodents such as mice.

The UC Riverside project, led by zur Nieden, will stimulate human pluripotent stem cells, which have the capacity to develop into any sort of cell, with agents that direct them to form bone cells. The cells will pass through the same developmental stages and be subject to the same molecular cues as in a human embryo. The researchers will expose the cells to selected chemicals at critical junctures, then assess them using advanced imaging and next-generation sequencing techniques.

Bone cells can develop through three different pathways. zur Nieden will use chemicals known to affect specific routes of bone development to look for patterns in how the chemicals affect these origins. The patterns will serve as blueprints for testing unknown chemicals. Next, the researchers will test unknown chemicals and compare them to previously compiled libraries of compounds that have already been tested in animals to see how accurate the petri dish, or in vitro, tests are for assessing risk.

A hallmark feature of bone-forming cells is that they make a bony matrix out of little crystals called hydroxyapatite, which eventually form calcium phosphate, the white stuff on the surface of all bones. Cost-saving visual analysis can help identify defects in calcium.

Calcium crystals appear white when viewed with your eyes, said zur Nieden. But when you view the cultures using phase contrast microscopy, it inverts the light so the normal crystals appear black. Abnormal crystals will have more white and shades of gray. You can use an image analysis algorithm to measure the blackness in images to determine if the calcium has formed correctly or not.

Scientists have known for a long time that animals differ from humans in important developmental and physiological ways, and that animal test results are not always reliable for people. Moreover, animal research is expensive and time-consuming, as well as increasingly untenable for ethical reasons. Non-animal alternatives have been in development for nearly 25 years, and some are already standard.

To the general public, the EPAs announcement seemed to come out of nowhere, said Volz, whose lab will sequence messenger RNA in chemical-exposed bone cells from zur Niedens lab to look for changes in gene expression. It didnt happen overnight. That train has already left the station.

Volz said the EPAs Science to Achieve Results Program, through which UC Riverside received the new grant, has been funding research on animal alternatives for more than 10 years.

The EPAs plan to end animal testing by 2035 follows up on earlier changes to the Toxic Substances Control Act, or TSCA, enacted in 1976. TSCA authorizes the EPA to regulate chemicals found in consumer products such as cleaning agents, furniture, paint, carpeting, clothing, and other consumer goods. Regulation under TSCA does not apply to chemicals in food, drugs, cosmetics, and pesticides, which are regulated under different laws.

Even after TSCA, thousands of common chemicals used in everything from plastic to sunscreen have never been tested for safety in humans. In 2016, Congress passed the Lautenberg Chemical Safety Act, amending TSCA to close the loophole for industrial chemicals. The law mandated the EPA to evaluate existing chemicals with clear and enforceable deadlines, and to develop risk-based chemical assessments. It promoted the use of non-animal testing methods, a move sought by both industry and animal rights groups.

The new EPA plan introduces an aggressive timeline for ramping up development of non-animal tests that can accurately predict toxicity in humans. Volz said the United States lags behind some other countries around the world, which have already greatly reduced animal testing. He said he interacts with fewer and fewer students interested in research involving animal experiments, and that our culture is shifting toward a desire to reduce animal suffering.

But neither Volz nor zur Nieden are sure animal testing can ever be replaced completely, a position echoed by the EPA memo, which states that after 2035, animal tests will be approved on a case-by-case basis. Some chemicals, for example, are not directly toxic to cells but become toxic after they are metabolized in the body.

If your result is that the chemical does not interfere with a human stem cell developing in a dish, how sure can you be thats not really happening in humans? The best way we have to assess that is an animal experiment, zur Nieden said. At the same time, we want to do this in an appropriate way. We need to think about, is this really necessary? Can we look at the question some other way?

zur Nieden thinks we need a tiered system, with in vitro tests weeding out the most toxic chemicals first, and animal tests used where in vitro tests dont reveal toxicity.

If you cannot fully replace an animal test with an in vitro method, you can at least decrease suffering of the animal. If you think about a highly toxic chemical that has effects on the mom as she is exposed during pregnancy as well as on the developing embryos, if you can use an in vitro test system to find all these strong toxic chemicals, you will not need to test them in an animal, she said.

Previous versions of the test system zur Nieden will use for the new musculoskeletal research have been able to identify embryotoxic chemicals for other tissues, such as heart tissue, with almost 100% accuracy.

Go here to read the rest:
Testing chemicals for birth defects using stem cells, not mice - UC Riverside